Compare GIS & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIS | SCLXW |
|---|---|---|
| Founded | 1866 | N/A |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9B | N/A |
| IPO Year | N/A | N/A |
| Metric | GIS | SCLXW |
|---|---|---|
| Price | $44.58 | $0.15 |
| Analyst Decision | Hold | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $53.27 | N/A |
| AVG Volume (30 Days) | ★ 7.9M | 4.0K |
| Earning Date | 12-17-2025 | 03-07-2025 |
| Dividend Yield | ★ 5.48% | N/A |
| EPS Growth | ★ 0.65 | N/A |
| EPS | ★ 4.63 | N/A |
| Revenue | ★ $18,776,700,000.00 | $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $42.79 | $0.18 |
| 52 Week High | $67.35 | $0.18 |
| Indicator | GIS | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 49.56 |
| Support Level | $43.43 | $0.10 |
| Resistance Level | $44.78 | $0.18 |
| Average True Range (ATR) | 1.01 | 0.03 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 63.56 | 77.74 |
General Mills is a global packaged-food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.